This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignee: Merck Sharp & Dohme LLC. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Innovations by Natalija Cernaka
Introduction
Natalija Cernaka is an accomplished inventor based in Cupertino, CA. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit plasma kallikrein. Her work is vital for treating various disease states that could benefit from such inhibition.
Latest Patents
Cernaka holds a patent for her invention titled "Plasma kallikrein inhibitors." This patent provides a compound of Formula (I) and pharmaceutical compositions that include one or more of these compounds. The methods outlined in her patent are aimed at treating or preventing conditions such as hereditary angioedema, uveitis, posterior uveitis, wet age-related macular edema, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. The compounds she developed are selective inhibitors of plasma kallikrein, showcasing her innovative approach to addressing complex medical issues.
Career Highlights
Cernaka is currently employed at Merck Sharp & Dohme LLC, where she continues to advance her research and development efforts. Her work at this prestigious company allows her to collaborate with other leading scientists and contribute to groundbreaking pharmaceutical innovations.
Collaborations
One of her notable coworkers is Alan C Cheng, with whom she collaborates on various projects. Their combined expertise enhances the potential for innovative solutions in the pharmaceutical industry.
Conclusion
Natalija Cernaka's contributions to the field of pharmaceuticals through her patent on plasma kallikrein inhibitors highlight her role as a leading inventor. Her work not only showcases her innovative spirit but also has the potential to significantly impact the treatment of various medical conditions.